Rigel Pharmaceuticals
Lilly cuts a $960m deal with Rigel on RIP kinase
Phil Taylor
central nervous system, Eli Lilly, Immunology and inflammation, partnering, Rigel Pharmaceuticals, RIPK1
0 Comment
Sobi gets EU nod for Doptelet in rare blood disorder ITP
Phil Taylor
Doptelet, ema, Grifols, immune thrombocytopenia, Novartis, Promacta, rare disease, regulatory approval, Rigel Pharmaceuticals, SOBI
0 Comment
Scotland backs Roche’s Rozlytrek for ROS1 lung cancer
Phil Taylor
Adcetris, Darzalex, Grifols, HEOR, Janssen, lung cancer, Oncology, Rigel Pharmaceuticals, Roche, Rozlytrek, SMC, Takeda
0 Comment
Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals
Phil Taylor
Jazz Pharmaceuticals, Mayzent, Novartis, Polivy, Rigel Pharmaceuticals, Roche
0 Comment